Expression of somatostatin receptors in human melanoma cell lines: Effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation

Journal of International Medical Research

Volumn 37, Issue 6, 2009, Pages 1813-1822

  Martinez Alonso, M ^a   Llecha, N ^a   Mayorga, M E ^a   Sorolla, A ^a   Dolcet, X ^a   Sanmartin, V ^a   Abal, L ^a   Casanova, J M ^a   Baradad, M ^a   Yeramian, A ^a   Egido, R ^a   Puig, S ^b   Vilella, R ^b   Matias Guiu, X ^a   Marti, Rosa M ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Apoptosis; Cell culture; Cell proliferation; Malignant melanoma; Octreotide; SOM230; Somatostatin analogues; Somatostatin receptors

Indexed keywords

OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 74949091875     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700617     Document Type: Article

References (30)

1. Lamberts SW, van der Lely AJ, Hofland LJ: New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol 2002; 146: 701-705.
2. Pawlikowski M, Melen-Mucha G: Perspectives of new potential therapeutic applications of somatostatin analogues. Neuro Endocrinol Lett 2003; 24: 21-27.
3. Bousquet C, Puente E, Buscail L, et al: Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001; 47(suppl 2): 30-39.
4. Hejna M, Schmidinger M, Raderer M: The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13: 653-668.
5. Pollak MN, Schally AV: Mechanisms of antineoplastic action of somatostatin analogues. Proc Soc Exp Biol Med 1998; 217: 143-152.
6. Reubi JC, Waser B, Schaer JC, et al: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtypeselective ligands. Eur J Nucl Med 2001; 28: 836-846.
7. Batista DL, Zhang X, Gejman R, et al: The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006; 91: 4482-4488.
8. Öberg K: Diagnosis and treatment of carcinoid tumours. Expert Rev Anticancer Ther 2003; 3: 863-877.
9. Hofland LJ, van der Hoek J, Feelders R, et al: Preclinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 2005; 28(11 suppl international): 36-42.
10. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 2005; 365: 687-701.
11. Markovic SN, Erickson LA, Rao RD, et al: Malignant melanoma in the 21st Century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007; 82: 490-513.
12. Ardjomand N, Ardjomand N, Schaffler G, et al: Expression of somatostatin receptors in uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2003; 44: 980-987.
13. Lum SS, Fletcher WS, O'Dorisio MS, et al: Distribution and functional significance of somatostatin receptors in malignant melanoma. World J Surg 2001; 25: 407-412.
14. Schwab R, Froidevaux S, Paku S, et al: Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours. Anticancer Res 2001; 21: 71-75.
15. Tejeda M, Gaal D, Barna K, et al: The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumour xenografts. Anticancer Res 2006; 23: 4061-4066.
16. Bruns C, Lewis I, Meno-Tetang G, et al: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716.
17. Hofland LJ, Lamberts SW: Somatostatin receptor subtype expression in human tumours. Ann Oncol 2001; 12(suppl 2): S31-S36.
18. Hofland LJ, Lamberts SWJ: The pathophysiological consequences of somatostatin receptor internalization. Endocr Rev 2003; 24: 28-47.
19. Weckbecker G, Briner U, Lewis I, et al: SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002; 143: 4123-4130.
20. Mayorga ME, Sanchis D, Perez de Santos A, et al: Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Res 2006; 16: 127-135.
21. Sorolla A, Yeramian A, Dolcet X, et al: Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanomaderived cell lines. Br J Dermatol 2008; 158: 496-504.
22. El-Salhy M, Starefeldt A: Direct effects of octreotide, galanin and serotonin on human colon cancer cells. Oncol Rep 2003; 10: 1723-1728.
23. Kubista M, Andrade JM, Bengtsson M, et al: The real-time polymerase chain reaction. Mol Aspects Med 2006; 27: 95-125.
24. 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Melanoma Res 2005; 15: 523-529.
25. Keller G, Schally AV, Nagy A, et al: Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. Int J Oncol 2006; 28: 1507-1513.
26. Bousquet C, Guillermet-Guibert J, Saint-Laurent N, et al: Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J 2006; 25: 3943-3954.
27. Guillermet-Guibert J, Saint-Laurent N, Davenne L, et al: Novel synergistic mechanism for sst2 somatostatin and TNFα receptors to induce apoptosis: crosstalk between NF-κB and JNK pathways. Cell Death Differ 2007; 14: 197-208.
28. Szende B, Horvatch A, Bökönyi G, et al: Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Br J Cancer 2003; 88: 132-136.
29. Adams RL, Adams IP, Lindow SW, et al: Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin Endocrinol 2004; 61: 431-436.
30. Arena S, Pattarozzi A, Corsaro A, et al: Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol Endocrinol 2005; 19: 255-267.